Medical treatments: In association or alone, their roles and their future perspectives - The Western experience

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 17, Issue 4, 2010, Pages 420-421

  Reig, Maria ^a   Bruix, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hepatocellular carcinoma; Sorafenib; Survival; Treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAF PROTEIN; SORAFENIB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; SHORT SURVEY; TUMOR RECURRENCE; LIVER TUMOR; MORTALITY; PATHOLOGY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PYRIDINES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 79952111879     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-009-0237-9     Document Type: Short Survey

References (13)

1. Parkin DM, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-17. (Pubitemid 37518510)
3. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-37.
4. Llovet JM, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698-711.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-36. (Pubitemid 43112690)
6. Yeo W, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532-8. (Pubitemid 41631953)
7. Kubo S, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann. Int Med. 2001;134(10):963-7.
8. Mazzaferro V, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44(6):1543-54. (Pubitemid 44970357)
9. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S141-3.
10. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.
11. Abou-Alfa GK, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293-300. (Pubitemid 46630787)
12. Strumberg D, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23(5):965-72. (Pubitemid 46202316)
13. Cheng AL, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25-34.